ReDiMoAMD
Age-related macular degeneration
Human organoid system based therapy discovery & development
Features
Project duration
36 months
Start :
End :
Project scale
European project
Allocated budget
Description
Age-related macular degeneration (AMD) causes vision loss due to photoreceptor (PR) degeneration, but disease models and therapies are missing. PR transplantation represents a promising treatment approach, but clinical translation remains a challenge. Our consortium aims to bridge two related research gaps: modeling of AMD pathology and therapy development (preventive and restorative). We developed a human retinal organoid (HRO) model with cellular and molecular AMD hallmarks in which PR degeneration occurs via cell extrusion, a pathology also described in AMD patients and correlating with ageing. PR extrusion mechanisms might offer targets to prevent AMD and to improve PR transplantation ? since both might share common and/or interrelated processes. For example, metabolic stress and inflammation, which are key in AMD, and known triggers of cell extrusion in other organs, might cause PR extrusion. Thus, the aims of the consortium are: (A) Decipher disease mechanisms by comparing our human and mouse AMD models, (B) determine function of inflammation (microglia) and metabolic changes, and (C) optimize PR transplantation in human AMD model. To achieve this, we will: 1. Optimize our platform for human PR transplantation into HROs, 2. identify regulators of AMD pathologies, and 3. modify potential regulators of PR extrusion to prevent pathogenesis and/or to stimulate PR transplant integration. Given our achievements, we will patent, publish and pursue towards clinical translation.
Programme
ERA-NET NEURON
Research into the diseases of the brain benefits from joint funding schemes by networks of funding agencies and ministries in Europe and beyond the European borders. The ERA-Net NEURON Cofund2, as a funding platform focused on neurological and mental disorders, holds a strategic position in bringing pre-clinical and clinical research communities closer together and fostering translational research, while covering the entire value chain.
JTC2020
The French National Research Agency will launch, in partnership with 23 countries, the second joint transnational call of the European Joint Programme on Rare Diseases for funding “Pre-clinical research to develop effective therapies for rare diseases”.